Urology

Our focus

Transforming lives with comprehensive treatment options to support kidney stone removal, prostate health, erectile restoration and continence.

Amy’s story

Delivering meaningful innovation

As a leader in urology, we are committed to impacting patient care by providing safe, quality and effective long-term treatment options. Our technologies, many of which are first-of-their kind and minimally invasive, help healthcare providers treat a wide range of common yet complex urological conditions affecting the patients they serve. We aim to improve the standard of care and fulfill unmet needs through continuous innovation and world-class support.

Advancing kidney stone management

Boston Scientific conducted research around the world to study how flexible ureteroscopy and percutaneous nephrolithotomy procedures are being conducted and how they can be improved. This research indicated that retrieving kidney stones is one of the most time-consuming steps during ureteroscopy procedures. The insights gathered resulted in StoneSmart™ Solutions — our vision to transform urologic stone care and address some of the biggest challenges urology providers face today.*

Expanding options for addressing prostate health

Boston Scientific has a growing portfolio of products that may impact the quality of life and clinical outcomes for people undergoing radiotherapy for prostate cancer and benign prostatic hyperplasia (BPH).

Transforming lives with prosthetic urology

Through therapy awareness, patient education, comprehensive clinical support and meaningful innovation, Boston Scientific is leading the way in fostering access to care for erectile dysfunction (ED) and stress urinary incontinence (SUI) patients.

Offering clinically proven treatment options to support pelvic health

Pelvic floor disorders are common – but the right therapy for a patient depends on their treatment goals. Our pelvic floor portfolio provides a range of clinically supported treatment options that allows us to meet patients where they are in their treatment journey.

In the U.S., 13,000 LithoVue^TM Elite Single-Use Digital Flexible Ureteroscopes have shipped reaching thousands of patients.¹

Over 325,000 SpaceOAR^TM and SpaceOAR Vue^TM units have been shipped for patients undergoing radiotherapy for prostate cancer.²

Designed for satisfaction as a long-term treatment option for erectile dysfunction, more than 500,000 AMS 700™ Inflatable Penile Prostheses have been sold worldwide.³

Conditions our customers treat with Boston Scientific products

Kidney Stones
Benign Prostatic Hyperplasia (BPH)
Erectile Dysfunction
Urinary and Fecal Incontinence
Pelvic Floor Disorders

~12%

of the population worldwide affected by kidney stone disease.⁴

50%

of men age 60+ affected by benign prostatic hyperplasia.⁵

50%

of men ages 40-70 are estimated to suffer from erectile dysfunction.⁶

~30M

U.S. adults ages 40 and older have bothersome symptoms of overactive bladder.⁷

Focus Areas

Stone Management
BPH Treatment Options
Hydrogel Perirectal Spacer Placed Prior to Prostate Cancer Radiation Therapy
Penile Implants for Erectile Dysfunction
Urinary Control Systems for Male Stress Urinary Incontinence
Mid-Urethral Slings and Urethral Bulking Agent for Female Stress Urinary Incontinence
Sacral Neuromodulation for Overactive Bladder and Fecal Incontinence

Product spotlights

Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology

Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology has been demonstrated to reduce operative times for lithotripsy and benign prostatic hyperplasia (BPH) treatments compared to standard holmium.^{8, 9, 10}

Learn more about the Lumenis Pulse

LithoVue™ Elite Single-Use Digital Flexible Ureteroscope

The LithoVue™ Elite Single-Use Digital Flexible Ureteroscope with intrarenal pressure (IRP) monitoring is designed to allow users to make informed, real-time clinical decisions in kidney stone management.

Learn more about the LithoVue Elite

AMS 700^TM Inflatable Penile Prosthesis with TENACIO^TM Pump

AMS 700™ Inflatable Penile Prosthesis is a category leading, physician-preferred implant designed to look and feel natural and provide long-term treatment for patients with erectile dysfunction. A new component for the AMS 700 is the TENACIO™ Pump, which was designed with exaggerated grips to facilitate pump control and ease of use.

Learn more about the AMS 700 Series

SpaceOAR^TM Hydrogel Spacers

SpaceOAR^TM hydrogel is an absorbable hydrogel that temporarily creates space between the prostate and rectum, designed to help reduce the radiation dose delivered to the rectum during prostate cancer radiation therapy. SpaceOAR has been demonstrated to help reduce the common side effects of prostate cancer radiotherapy such as late rectal toxicity, urinary incontinence and urinary toxicity.^{11, 12} SpaceOAR Vue^TM is the next generation hydrogel spacer that offers visibility via CT Scan, designed to help physicians improve contouring accuracy and consistently position patients receiving prostate cancer radiation.

Learn more about the SpaceOar Hydrogel Spacers

Rezūm™ Water Vapor Therapy

Rezūm™ Water Vapor Therapy is a minimally invasive treatment intended to alleviate the cause of BPH – an enlarged prostate. This therapy delivers sterile steam directly to the targeted tissue. Clinical studies demonstrated that over time the steam reduces the volume of the prostate to relieve BPH symptoms, while preserving sexual function.^{13, 14}

Learn more about the Rezūm System

Upsylon^TM Y-Mesh

Upsylon^TM Y-Mesh is designed to treat patients suffering from pelvic organ prolapse. The durable design is intended to resist tearing.

Learn more about Upsylon Y-Mesh

Risk Information

There are risks associated with all medical procedures. Please talk with your doctor about the risks and benefits associated with Boston Scientific medical devices.

AMS 700™ Inflatable Penile Prosthesis indications, safety and warnings

LithoVue™ Single-Use Digital Flexible Ureteroscope indications, safety and warnings

LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System indications, safety and warnings

Lumenis Pulse™ 120H Holmium Laser System with MOSES™ Technology indications, safety and warnings

Rezūm™ Water Vapor Therapy indications, safety and warnings

SpaceOAR™ Hydrogel Spacers indications, safety and warnings

Upsylon™ Y-Mesh indications, safety and warnings

Potential risks for Upsylon™ Y-Mesh and Polyform™ Synthetic Mesh: Potential adverse events, any of which may be ongoing, include but are not limited to: Abscess, Adhesion formation, Allergic reaction (hypersensitivity), Bruising, Bleeding (hematoma formation), Constipation, Dehiscence, De novo detrusor instability, Dyspareunia, Pain with intercourse that may not resolve, Sexual dysfunction; including the inability to have intercourse, Erosion into organs; exposure/extrusion into vagina, Exposed mesh may cause pain or discomfort to the patient’s partner during intercourse, Failure to resolve a patient’s prolapse, Fistula formation (acute or chronic), Foreign body reaction (acute or chronic), Granulation tissue formation, Hemorrhage, Infection, Inflammation (acute or chronic), Injury to ureter, Scarring/scar contracture, Mesh contracture, Tissue contracture, Necrosis, Nerve injury, Organ perforation, Pain (pelvic, vaginal, groin/thigh, dyspareunia) (acute or chronic), Perforation or laceration of vessels, nerves, bladder, or bowel may occur during placement, Post-operative bowel obstruction, Prolapse/recurrent prolapse, Vaginal shortening or stenosis that may result in dyspareunia and/or sexual dysfunction, Voiding dysfunction (incontinence, temporary or permanent lower urinary tract obstruction, difficulty urinating, pain with urination, overactive bladder, and retention). The occurrence of one or more of these complications may require treatment or surgical intervention. In some instances, the complication may persist as a permanent condition after the surgical intervention or other treatment. Removal of mesh or correction of mesh-related complications may involve multiple surgeries. Complete removal of mesh may not be possible and additional surgeries may not always fully correct the complications.

Boston Scientific acquired the global surgical business of Lumenis Ltd. Lumenis Pulse™ 120H is the registered product name. Lumenis Pulse™ 120H with MOSES Technology is manufactured and sold by Boston Scientific. Lumenis is a registered trademark of Lumenis Be.

Rx Only

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a physician.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

Sources

Based on Boston Scientific sales data for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope as of March 2025.
Based on units shipped for SpaceOAR™ Hydrogel and SpaceOAR Vue™ as of 2024.
Based on Boston Scientific sales data for AMS 700™ as of May 2024.
Alelign T, Petros B. Kidney stone disease: An update on current concepts. Adv Urol. 2018 Feb 4;3068365.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3–S14.
Cleveland Clinic. “Erectile Dysfunction.” https://my.clevelandclinic.org/health/diseases/10035-erectile-dysfunction
Coyne, et al. “National community prevalence of overactive bladder in the United States stratified by sex and age.” Urology. Volume 77, Issue 5, P1081-1087, MAY 2011. DOI: https://doi.org/10.1016/j.urology.2010.08.039
Ibrahim A, Elhilali MM, Fahmy N, et al. Double-blinded prospective randomized clinical trial comparing regular and Moses modes of holmium laser lithotripsy. J Endourol. 2020 May;34(5):624-8.
Whiles BB, Martin AJ, Brevik A, et al. Utilization of Moses modulated pulse mode results in improved efficiency in holmium: YAG laser ablation of the prostate. Urology. 2021 Mar;149:18792.
Kavoussi NL, Nimmagadda N, Robles J, et al. MOSES technology for holmium laser enucleation of the prostate: A prospective double‐blind randomized control trial. J Urol. 2021 Jul;206(1):104-8.
Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971-977.
Hamstra DA, Mariados N, Sylvester J, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976-985.
McVary KT, Gittelman MC, Goldberg KA. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urology. 2021 Sep;206(3):715-724.
Mynderse L A, Hanson D, Robb R et al. Rezūm system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. J Urology. 2015 Jul;86(1):122-7.

*Market research study sponsored by Boston Scientific. Data on file.

My account